GlassScriptPhysician profile
Mohamed H El Dinali
NPI 1134499858
$7,033.27
in general payments reported to CMS, 2019-2025
48 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $480 · 2021: $549 · 2022: $540 · 2023: $976 · 2024: $1,673 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,090 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.42 |
| Education | $123.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $982.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $743.63 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astellas Pharma US INC | $528.33 | 2019-2025 | Padcev, Vyloy |
| Daiichi Sankyo INC. | $489.20 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $487.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $419.05 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $341.47 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Amgen INC. | $314.26 | 2019-2023 | Lumakras |
| Celgene Corporation | $263.23 | 2019-2025 | Opdualag, Reblozyl, Breyanzi |
| Abbvie INC. | $214.69 | 2019-2025 | |
| Janssen Biotech, INC. | $204.92 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Regeneron Healthcare Solutions, INC. | $159.79 | 2019-2025 | Libtayo |
| Genmab U.S., INC. | $135.77 | 2023-2025 | Tivdak, Epkinly |
| Eisai INC. | $122.78 | 2019-2024 | |
| Gilead Sciences, INC. | $120.75 | 2021-2025 | Trodelvy |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $115.49 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Adaptive Biotechnologies Corporation | $114.10 | 2021-2023 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $105.31 | 2019-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $103.89 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $99.25 | 2019-2023 | Padcev |
| Foundation Medicine, INC. | $90.68 | 2019 | |
| Lilly USA, LLC | $90.22 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $86.61 | 2023-2024 | Fotivda |
| Array Biopharma INC | $77.96 | 2019-2025 | Xalkori, Lorbrena, Braftovi |
| Genzyme Corporation | $74.30 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $64.93 | 2019-2024 | Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $45.31 | 2019 | |
| Stemline Therapeutics INC. | $41.39 | 2024-2025 | Orserdu |
| Tesaro, INC. | $36.03 | 2019 | |
| Emd Serono, INC. | $35.73 | 2023 | Bavencio |
| Novocure INC. | $28.81 | 2022-2025 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $27.51 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.37 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.95 | 2019 | |
| Clovis Oncology, INC. | $23.02 | 2019-2022 | |
| Kite Pharma, INC. | $20.70 | 2023 | |
| Karyopharm Therapeutics INC. | $20.42 | 2022 | |
| Kyowa Kirin, INC. | $18.32 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.76 | 2019 | |
| Tempus Ai, INC | $14.33 | 2024 | |
| Exelixis INC. | $13.93 | 2024 | Cabometyx |
| Beigene USA, INC. | $13.73 | 2021 | |
| Tersera Therapeutics LLC | $13.55 | 2025 | Zoladex |
| Mirati Therapeutics, INC. | $13.12 | 2024 | Krazati |
| Genentech USA, INC. | $12.47 | 2022 | |
| Taiho Oncology, INC. | $12.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed El Dinali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.